Key result
WHO standard anti-CHIKV antibodies protect naïve mice from lethal infection for 14 days.
Why the study?
To enhance the value of the WHO International Standard (1502/19) for anti-CHIKV antibodies by assessing its in vivo immune protection to determine the protective titre.
Does the WHO International Standard (1502/19) for anti-CHIKV antibodies provide in vivo immune protection against lethal CHIKV infection in a mouse model?
Does the WHO International Standard (1502/19) for anti-CHIKV antibodies provide in vivo immune protection against lethal CHIKV infection in a mouse model?
The WHO International Standard for anti-CHIKV antibodies provides standalone humoral immune protection in vivo, establishing a standardized protective threshold for future vaccine evaluation.
Provides murine protective titre benchmark; leaves open human translation and vaccine trial validation.
Chikungunya virus (CHIKV) is an arthritogenic mosquito-borne virus of public health concern, causing incapacitating febrile illness and, in some cases, chronic long-lasting recurring arthritis. The epidemic potential and unpredictable nature of CHIKV outbreaks provided a stimulus for establishing the WHO International Standard (1502/19) for anti-CHIKV antibodies in 2022. To enhance the value of this serological material, the in vivo immune protection of 1502/19 was assessed to determine the protective titre. Dilutions of 1502/19 were administered to naïve mice and circulating antibody levels measured prior to challenge 24 h later with CHIKV isolate LR2006-OPY1. Mice administered with undiluted 1502/19 survived an otherwise lethal infection to the end of the study (14 days post-challenge), indicating protection was afforded by 1502/19 and establishing a protective titre can be attained. Our results confirm that standalone humoral immunity can provide protection and aid in future vaccine evaluation by elucidating a standardised protective threshold.
No takes yet. Share an insight, caveat, or question.
Dowall et al. (2026) studied Chikungunya virus (CHIKV) infection. WHO International Standard (1502/19) for anti-CHIKV antibodies was evaluated on Survival. Administration of undiluted WHO International Standard (1502/19) for anti-CHIKV antibodies protected naïve mice from an otherwise lethal CHIKV infection up to 14 days post-challenge.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: